Abstract
Protein trans-splicing based dual-vector factor VIII (FVIII) gene delivery is adversely affected by less efficiency of protein splicing. We sought to increase the amount of spliced FVIII protein and plasma coagulation activity in dual-vector FVIII transgene in mice by means of strengthening the interaction of inteins, protein splicing elements, thereby facilitating protein trans-splicing. Dual-vector delivery of the FVIII gene in cultured cells showed that replacement of Met226 in the heavy chain and Asp1828 in the light chain with Cys residues could facilitate inter-chain disulfide linking and improve protein trans-splicing, increasing the levels of spliced FVIII protein. In this study, C57BL/6 mice were coadministered dual vectors of intein-fused human FVIII heavy chain and light chain with Cys mutations via portal vein injection into the liver. Forty-eight hours post-injection, plasma was collected and analyzed for FVIII antigen concentration and coagulation activity. These mice showed increased circulating FVIII heavy chain polypeptide (442±151 ng mL−1 vs. 305±103 ng mL−1) and coagulation activity (1.46±0.37 IU m−1 vs. 0.85±0.23 IU mL−1) compared with control mice co-administered dual vectors expressing the heavy and light chains of wild-type FVIII. Moreover, coagulation activity was similar to that of mice receiving a single vector expressing FVIII (1.79±0.59 IU mL−1). These findings indicate that improving protein trans-splicing by inter-chain disulfide bonding is a promising approach for increasing the efficacy of dual-vector based FVIII gene transfer.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Zhu F X, Liu Z L, Chi X Y, et al. Protein trans-splicing based dual-vector delivery of the coagulation factor VIII gene. Sci China Life Sci, 2010, 53: 683–689
Wu H, Xu M Q, Liu X Q. Protein trans-splicing and functional mini-inteins of a cyanobacterial dnaB intein. Biochim Biophys Acta, 1998, 1387: 422–432
Scallan C D, Liu T, Parker A E, et al. Phenotypic correction of a mouse model of hemophilia A using AAV2 vectors encoding the heavy and light chains of FVIII. Blood, 2003, 102: 3919–3926
Zhang K, Shen X, Wu J, et al. Endoplasmic reticulum stress activates cleavage of CREBH to induce a systemic inflammatory response. Cell, 2006, 124: 587–599
Zhu F X, Liu Z L, Miao J, et al. Cys mutation of Met662 and Asp1828 strengthens splicing of coexpressed B-domain-deleted FVIII heavy and light chains by intein. Chin J Biochem Mol Biol, 2012, 28: 234–239
Burton M, Nakai H, Colosi P, et al. Coexpression of factor VIII heavy and light chain adeno-associated viral vectors produces biologically active protein. Proc Natl Acad Sci USA, 1999, 96: 12725–12730
Chen L X, Zhu F X, Li J, et al. The enhancing effects of the light chain on heavy chain secretion in split delivery of factor VIII gene. Mol Ther, 2007, 15: 1856–1862
Swaroop M, Moussalli M, Pipe S W, et al. Mutagenesis of a potential immunoglobulin-binding protein-binding site enhances secretion of coagulation factor VIII. J Biol Chem, 1997, 272: 24121–24124
Arruda V R, Stedman H H, Haurigot V, et al. Peripheral transvenular delivery of adeno-associated viral vectors to skeletal muscle as a novel therapy for hemophilia B. Blood, 2010, 115: 4678–4688
Niemeyer G P, Herzog R W, Mount J, et al. Long-term correction of inhibitor-prone hemophilia B dogs treated with liver-directed AAV2-mediated factor IX gene therapy. Blood, 2009, 113: 797–806
Sarkar R, Mucci M, Addya S, et al. Long-term efficacy of adeno-associated virus serotypes 8 and 9 in hemophilia a dogs and mice. Hum Gene Ther, 2006, 17: 427–439
Kaufman R J, Wasley L C, Dorner A J. Synthesis, processing, and secretion of recombinant human factor VI11 expressed in mammalian cell. J Biol Chem, 1988, 263: 6352–6362
Sabatino D S, Lange A M, Altynova E S, et al. Efficacy and safety of long-term prophylaxis in severe hemophilia A dogs following liver gene therapy using AAV vectors. Mol Ther, 2011, 19: 442–449
Mah C, Sarkar R, Zolotukhin I, et al. Dual vectors expressing murine factor VIII result in sustained correction of hemophilia A mice. Hum Gene Ther, 2003, 14: 143–152
Pipe S W. Coagulation factors with improved properties for hemophilia gene therapy. Semin Thromb Hemost, 2004, 30: 227–237
Miao H Z, Sirachainan N, Palmer L, et al. Bioengineering of coagulation factor VIII for improved secretion. Blood, 2004, 103: 3412–3419
Gale A J, Radtke K P, Cunningham M A, et al. Intrinsic stability and functional properties of disulfide bond-stabilized coagulation factor VIIIa variants. J Thromb Haemost, 2006, 4: 1315–1322
Zhu F X, Liu Z L, Miao J, et al. Enhanced plasma factor VIII activity via Cys mutation in mice using dual vectors. Sci China Life Sci, 2012, 55: 521–526
Zhu F X, Yang S D, Liu Z L, et al. The effect of a secretion-enhanced heavy chain on improving intein-based dual-vector co-delivery of a full-length factor VIII gene. Chin Sci Bull, 2011, 56: 158–163
Kaufman R J. Genetic engineering of factor VIII. Nature, 1989, 342: 207–208
Vila-Perello M, Muir T W. Biological applications of protein splicing. Cell, 2010, 143:191–200
Author information
Authors and Affiliations
Corresponding author
Additional information
This article is published with open access at Springerlink.com
Rights and permissions
Open Access This article is distributed under the terms of the Creative Commons Attribution 2.0 International License (https://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
About this article
Cite this article
Zhu, F., Liu, Z., Wang, X. et al. Inter-chain disulfide bond improved protein trans-splicing increases plasma coagulation activity in C57BL/6 mice following portal vein FVIII gene delivery by dual vectors. Sci. China Life Sci. 56, 262–267 (2013). https://doi.org/10.1007/s11427-013-4455-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11427-013-4455-7